Circulating plasma adiponectin, an adipocyte-derived protein, has been shown to be decreased in obese subjects as well as in patients with type 2 diabetes and also in subjects who do not have diabetes, but are insulin resistant. We assessed the relationship between plasma levels of adiponectin, the metabolic syndrome and the occurrence of small dense LDL particles (pattern B) in 101 clinically healthy middle-aged subjects recruited from the general population. Low adiponectin levels were associated with the metabolic syndrome and low-density lipoprotein (LDL) particle size (r = .55, P < .001). The relationship between adiponectin and LDL particle size remained in a multiple regression model, in which adiponectin and total body fat explained 30% of the variability in LDL particle size. Furthermore, subjects in the lowest tertile of adiponectin had an increased risk of having pattern B (risk odds ratio [ROR] = 5.6). Because this was a cross-sectional study, no conclusions can be drawn about causality. This is the first population-based study in man demonstrating a relationship between small dense LDL particles and adiponectin.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Metabolism - Clinical and Experimental
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Hypoadiponectinemia in obesity and type 2 diabetes.J Clin Endocrinol Metab. 2001; 86: 1930-1935
- Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans.Diabetes. 2002; 51: 1884-1888
- Quantitative trait loci on chromosomes 3 and 17 influence phenotypes of the metabolic syndrome.Proc Natl Acad Sci USA. 2000; 97: 14478-14483
- The small, dense LDL phenotype and the risk of coronary heart disease.Diabetes Metab. 1999; 25: 199-211
- The metabolic syndrome, LDL particle size, and atherosclerosis.Arterioscler Thromb Vasc Biol. 2000; 20: 2140-2147
- Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation.Diabet Med. 1998; 15: 539-553
- The euglycemic hyperinsulinemic clamp examination.Scand J Clin Lab Invest. 2000; 60: 27-36
- Estimation of the concentration of low density lipoprotein in plasma, without use of the preparative ultracentrifuge.Clin Chem. 1972; 18: 499-502
- Decreased plasma adiponectin concentrations in women with dyslipidemia.J Clin Endocrinol Metab. 2002; 87: 2764-2769
- Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism.Diabetes. 2003; 52: 239-243
- Fasting serum adiponectin concentration is reduced in Indo-Asian subjects and is related to HDL cholesterol.Diabetes Obes Metab. 2003; 5: 131-135
- Relationship of LDL size to insulin sensitivity in normoglycemic men.Arterioscler Thromb Vasc Biol. 1997; 17: 1447-1453
- A prospective, population-based study of low density lipoprotein particle size as a risk factor for ischemic heart disease in men.Can J Cardiol. 2001; 17: 859-865
- Lipoprotein lipase activity in skeletal muscle is related to insulin sensitivity.Arterioscler Thromb Vasc Biol. 1991; 11: 1192-1203
- Changes of lipolytic enzymes cluster with insulin resistance syndrome. Botnia Study Group.Diabetologia. 1995; 38: 344-350
Accepted: June 11, 2003
Received: March 13, 2003
☆Supported by grants from the Swedish Heart-Lung Foundation, the Swedish Medical Research Council (12270 and 10880), AstraZeneca Mölndal, Sweden. J.H. is Medical Adviser at AstraZeneca R&D, Mölndal, Sweden.
© 2003 Elsevier Inc. Published by Elsevier Inc. All rights reserved.